Literature DB >> 22119819

The diagnostic value of EMA expression in the renal parenchyma tumors.

Aurora Alexa1, Flavia Baderca, Rodica Lighezan, Delia Elena Zăhoi, D Izvernariu.   

Abstract

Renal parenchyma tumors are a heterogeneous group of malignancies that are difficult to diagnose and classify. Immunohistochemistry begun to be routinely used for the diagnosis of these tumors. Panels of antibodies are developed for the diagnostic assessment of these tumors, which include cytokeratins, epithelial membrane antigen and vimentin. Epithelial membrane antigen (EMA) is expressed by most of the tumor cell types. Forty-seven specimens of renal parenchyma tumors were studied immunohistochemically for the expression of EMA. In the majority of the cases, clear cells carcinoma was positive for EMA (25/33, 75.70%). All of the papillary carcinomas were positive, with different staining patterns between the two subtypes. The two cases of chromophobe cells carcinomas were intensely positive with a granular cytoplasmic staining pattern. The mixed epithelial-stromal tumor was negative for EMA in both of the components. Out of the three cases of sarcomatoid carcinomas, one was negative, one was weakly positive (+1) and the last was positive (+2). Intensely positive normal tubes were caught by the tumor proliferation in the negative case and in the negative stained areas of the weakly positive case.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22119819

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  2 in total

Review 1.  Old, New, and Emerging Immunohistochemical Markers in Pheochromocytoma and Paraganglioma.

Authors:  Veronica K Y Cheung; Anthony J Gill; Angela Chou
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Assessment of Mitochondrial Dysfunction and Monoamine Oxidase Contribution to Oxidative Stress in Human Diabetic Hearts.

Authors:  O M Duicu; R Lighezan; A Sturza; R Balica; A Vaduva; H Feier; M Gaspar; A Ionac; L Noveanu; C Borza; D M Muntean; C Mornos
Journal:  Oxid Med Cell Longev       Date:  2016-04-13       Impact factor: 6.543

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.